Y. Levy

Discipline

Psychologie (1) Economies et finances (1)

Type de document

Articles (15)

Co-auteur

Date

Source

Mot-clé

Human beings (9) gène (8) Immunodeficiency (8) Immunoglobulins (8) Vaccination (7) T cells (7) Patients (7) Vaccination (7) Patients (7) protéine (6) SIDA (6) puits (5) infection (5) ADN (5) vecteur (5) Mice (5) Manufactures (5) Infection (5) Immunoglobulin G (5) DNA (5) Cytokines (5) B cells (5) Animals (5) anticorps (4) immunité (4) maladie (4) Treatment (4) Control (4) Death (4) Vaccines (4)

Documents écrit par Y. Levy (15) | parle de Y. Levy (0)

Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19.
H. Hocini et al.
Correction to: Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID‑19.
H. Hocini et al.
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein.
B. Perdiguero et al. (2023)
Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients.
A. Wiedemann et al. (2022)
A highly potent antibody effective against SARS-CoV-2 variants of concern.
C. Pellaton et al. (12 oct. 2021)
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.
R. Marlin et al. (1 sept. 2021)
The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients.
M. Perreau et al. (9 août 2021)
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.
Y. Lévy et al. (23 juil. 2021)
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Y. Lévy et al. (12 avr. 2021)
TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.
V. Godot et al.
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
Y. Lévy et al.
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
B. Perdiguero et al. (2019)
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.
G. Zurawski et al. (2016)
Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders.
M. Perreau et al. (2014)
HIV infection en route to endogenization: two cases
Philippe Colson et al. (2014)